Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors:: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients

被引:161
作者
Guillevin, L
Cohen, P
Mahr, A
Arène, JP
Mouthon, L
Puéchal, X
Pertuiset, E
Gilson, B
Hamidou, M
Lanoux, P
Bruet, A
Ruivard, M
Vanhille, P
Cordier, JF
机构
[1] Univ Paris 13, UPRES EA 3409, Rech Clin & Therapeut, Hop Avicenne,Dept Internal Med, F-93009 Bobigny, France
[2] Ctr Hosp, Le Mans, France
[3] Ctr Hosp, Pontoise, France
[4] Ctr Hosp, Verdun, France
[5] Hop Hotel Dieu, Nantes, France
[6] Ctr Hosp, Charleville Mezieres, France
[7] Ctr Hosp, Poissy, France
[8] Ctr Hosp Univ, Clermont Ferrand, France
[9] Ctr Hosp, Valenciennes, France
[10] Ctr Hosp, Lyon, France
来源
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH | 2003年 / 49卷 / 01期
关键词
polyarteritis nodosa; microscopic polyangiitis; therapy; cyclophosphamide;
D O I
10.1002/art.10922
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Because the optimal cyclophosphamide (CY) treatment duration for severe polyarteritis nodosa (PAN) without vir-us infection and microscopic polyangiitis (MPA) has not been established, we conducted a trial to compare the effectiveness of 6 versus 12 CY pulses given in combination with corticosteroids (CS). Methods. Sixty-five (18 PAN, 47 MPA) previously untreated patients were randomized to receive 12 (n = 34) or 6 (n 31) CY pulses combined with CS. PAN and MPA were histologically proven or met ACR criteria. All patients presented greater than or equal to1 factor of severity according to the five factor score (FFS). CY pulses were administered every 2 weeks for 1 month, then every 4 weeks. The end point of the study was the number of events (relapses and/or deaths) occurring in each group, analyzed according to an intention-to-treat strategy. The outcome was evaluated by Cox proportional hazards analysis. Results. The baseline characteristics were similar for both groups. The mean (+/- SD) followup was 32 +/- 21 months. Survival analysis showed a significantly lower relapse probability (P = 0.02; hazards ratio [HR] = 0.34) and higher event-free survival (P = 0.02, HR = 0.44) for the 12 CY-pulse group while the mortality rates were not significantly different (P = 0.47). Conclusion. These results suggest that 6 CY pulses are less effective than 12 CY pulses to treat severe PAN and MPA, particularly with respect to the risk of relapses.
引用
收藏
页码:93 / 100
页数:8
相关论文
共 23 条
  • [1] Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis
    Adu, D
    Pall, A
    Luqmani, RA
    Richards, NT
    Howie, AJ
    Emery, P
    Michael, J
    Savage, COS
    Bacon, PA
    [J]. QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1997, 90 (06): : 401 - 409
  • [2] BACON PA, 1998, CLIN EXP IMMUNOL, V112, pS59
  • [3] Bartolucci P, 2001, ARTHRITIS RHEUM, V44, pS56
  • [4] COX DR, 1972, J R STAT SOC B, V34, P187
  • [5] Gayraud M, 2001, ARTHRITIS RHEUM, V44, P666, DOI 10.1002/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO
  • [6] 2-A
  • [7] Gayraud M, 1997, BRIT J RHEUMATOL, V36, P1290
  • [8] CORTICOSTEROIDS PLUS PULSE CYCLOPHOSPHAMIDE AND PLASMA EXCHANGES VERSUS CORTICOSTEROIDS PLUS PULSE CYCLOPHOSPHAMIDE ALONE IN THE TREATMENT OF POLYARTERITIS-NODOSA AND CHURG-STRAUSS-SYNDROME PATIENTS WITH FACTORS PREDICTING POOR-PROGNOSIS - A PROSPECTIVE, RANDOMIZED TRIAL IN 62 PATIENTS
    GUILLEVIN, L
    LHOTE, F
    COHEN, P
    JARROUSSE, B
    LORTHOLARY, O
    GENEREAU, T
    LEON, A
    BUSSEL, A
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (11): : 1638 - 1645
  • [9] Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome - A prospective study in 342 patients
    Guillevin, L
    Lhote, F
    Gayraud, M
    Cohen, P
    Jarrousse, B
    Lortholary, O
    Thibult, N
    Casassus, P
    [J]. MEDICINE, 1996, 75 (01) : 17 - 28
  • [10] A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis
    Guillevin, L
    Cordier, JF
    Lhote, F
    Cohen, P
    Jarrousse, B
    Royer, I
    Lesavre, P
    Jacquot, C
    Bindi, P
    Bielefeld, P
    Desson, JF
    Détrée, F
    Dubois, A
    Hachulla, E
    Hoen, B
    Jacomy, D
    Seigneuric, C
    Lauque, D
    Stern, M
    Longy-Boursier, M
    [J]. ARTHRITIS AND RHEUMATISM, 1997, 40 (12): : 2187 - 2198